News & Updates

712, 2018

New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment

December 7th, 2018|

PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment BluePrint reclassified 85 percent of tumors identified as HER2-amplified by IHC/FISH to non-HER2 Read More

512, 2018

New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions

December 5th, 2018|

PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium IRVINE, CA, AMSTERDAM, Read More

1411, 2018

Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients

November 14th, 2018|

 PRESS RELEASE Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients New data from the trial shows that a Read More